Company |
Partner |
Amt. (M) |
Details |
Date |
TOTAL: $84.85M (Year to Date: $1,029.21M) | ||||
Aduro Biotech Inc. (Berkeley, Calif.) |
Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) |
ND |
For the acceptance of an investigational new drug application by the FDA for ADU-741 |
12/18/15 |
Affibody AB (Solna, Sweden) |
Daiichi Sankyo Co. Ltd. (Tokyo) |
ND |
For initiation of a phase I study |
12/2/15 |
Compugen Ltd. (Tel Aviv, Israel) |
Bayer AG (Leverkusen, Germany) |
ND |
As part of the collaboration for antibody-based cancer therapeutics against the Compugen-discovered immune checkpoint regulators CGEN-15001T and CGEN-15022, which showed encouraging functional activity in preclinical models of cancer immunotherapy |
12/14/15 |
CTI Biopharma Corp. (Seattle) |
Teva Pharmaceutical Industries Ltd. (Jerusalem) |
$10 |
For the achievement of sales milestones for Trisenox (arsenic trioxide) |
12/15/15 |
Genmab A/S (Copenhagen) |
Johnson & Johnson (New Brunswick, N.J.) |
$5 |
As part of its daratumumab collaboration, and its progress in the ongoing phase II study testing it in non-Hodgkin lymphoma |
12/10/15 |
Genmab A/S (Copenhagen) |
Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) |
$3.5 |
$3M for Janssen's selection of a clinical candidate for the sixth program in the Duobody technology platform collaboration; an additional $500,000 was achieved for preclinical progress in the same program |
12/21/15 |
Genmab A/S (Copenhagen) |
Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) |
$3 |
For Janssen's selection of a clinical candidate for the seventh program in the Duobody technology platform collaboration |
12/22/15 |
Ionis Pharmaceuticals Inc. (Carlsbad, Calif.) |
Biogen Inc. (Cambridge, Mass.) |
$5 |
Associated with the validation of an undisclosed target to treat patients with an undisclosed neurological disorder |
12/23/15 |
Lightlake Therapeutics Inc. (New York) |
Adapt Pharma Ltd. (Dublin) |
$2 |
For the FDA approval of Narcan for emergency treatment of known or suspected opioid overdose |
12/16/15 |
Orexo AB (Uppsala, Sweden) |
Prostrakan Group plc (Lalshiels, Scotland) |
$7.6 |
For 2015 sales of Abstral (fentanyl) in Europe surpassing €67.5M (US$74.2M) |
12/14/15 |
Pieris Pharmaceuticals Inc. (Boston) |
Sanofi SA (Paris) |
ND |
For Sanofi's decision to continue advancing the tetraspecific anticalin-based program for infectious disease; the drug candidate selectively binds four classes of siderophores produced by Pseudomonas aeruginosa, altogether comprising 10 distinct targets |
12/1/15 |
Regulus Therapeutics Inc. (La Jolla, Calif.) |
Astrazeneca plc (London) |
$10 |
For the start of dosing in a phase I study of RG-125 to treat non-alcoholic steatohepatitis |
12/21/15 |
Spark Therapeutics Inc. (Philadelphia) |
Pfizer Inc. (New York) |
$15 |
As part of the firms' global collaboration for the potential development and commercialization of SPK-FIX product candidates for the treatment of hemophilia B |
12/11/15 |
Summit Therapeutics plc (Oxford, UK) |
University of Oxford |
ND |
Following nomination of two series of novel utrophin modulators to progress into lead optimization studies |
12/3/15 |
Vectura Group plc (Chippenham, UK) |
Novartis AG (Basel, Switzerland) |
$3.75 |
For enrollment of the first patients in the phase III trial of QVM149 to treat moderate to severe asthma |
12/10/15 |
Zealand Pharma A/S (Copenhagen) |
Sanofi SA (Paris) |
$20 |
For the NDA submission of a combination of basal insulin (Lantus; insulin glargine) and its glucagon-like peptide 1 receptor agonist Lyxumia (lixisenatide) for treating adults with type 2 diabetes |
12/24/15 |
|
Notes Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. This chart includes only biotech companies that develop therapeutics. ND = Not disclosed. | ||||